Skip to main content
SpringerLink
Log in

Topotecan

  • Chapter
Extravasation of Cytotoxic Agents

  • 101 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Original articles

  1. Oostweegel LM, van Warmerdam LJ, Schot M, et al: Extravasation of topotecan, a report of two cases. J Oncol Pharm Practice 3: 115–116, 1997.

    Article  Google Scholar 

Secondary literature

  1. van Gemmern R: Gewebstoxizität und Paravasatbehandlung neuer Zytostatika. Krankenhauspharmazie 17: 471–473, 1996.

    Google Scholar 

  2. Summary of product characteristics Hycamtin® (Austria), SmithKline Beecham, March 1999.

    Google Scholar 

  3. Berdel WE, Schmoll HJ, Küchele T, et al: Prävention und Therapie von Paravasaten/Extravasaten. In: Schmoll HJ, Höffken K, Possinger K (eds) Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie. Springer, Vol 1, 3rd edition: 1689–1701, 1999.

    Google Scholar 

  4. Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.

    Google Scholar 

  5. Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria

    Ines Mader MD

  2. SMZ Floridsdorf, Krankenhaus und Geriatriezentrum, Vienna, Austria

    Patrizia E. Fürst-Weger Mag. pharm

  3. Clinical Division of Oncology, Department of Medicine I, University Hospital, Vienna, Austria

    Robert M. Mader DSc

  4. Anstaltsapotheke, Landeskrankenhaus — Universitätskliniken Innsbruck, Austria

    Elisabeth I. Semenitz MD, Mag. pharm

  5. Kaiser-Franz-Josef Hospital, Vienna, Austria

    Robert Terkola PharmD (Head of Pharmacy)

  6. Apotheke LKH-Univ.-Klinikum Graz, Austria

    Sabine M. Wassertheurer Mag. pharm.

Authors
  1. Ines Mader MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrizia E. Fürst-Weger Mag. pharm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert M. Mader DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elisabeth I. Semenitz MD, Mag. pharm
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert Terkola PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sabine M. Wassertheurer Mag. pharm.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Wien

About this chapter

Cite this chapter

Mader, I., Fürst-Weger, P.E., Mader, R.M., Semenitz, E.I., Terkola, R., Wassertheurer, S.M. (2003). Topotecan. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3710-9_48

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-3710-9_48

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-3712-3

  • Online ISBN: 978-3-7091-3710-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation